Details of the Drug

General Information of Drug (ID: DMWNRZT)

Drug Name
Basiliximab
Synonyms Simulect (TN)
Indication
Disease Entry ICD 11 Status REF
Organ transplant rejection NE84 Approved [1]
Therapeutic Class
Immunomodulatory Agents
Affected Organisms
Humans and other mammals
ATC Code
L04AC02: Basiliximab
L04AC: Interleukin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Sequence
>heavy chain
QLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQ
KFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSSASTKG
PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
QIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPAR
FSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIKRTVAAPSVFIFPPSDE
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
ADYEKHKVYACEVTHQGLSSPVTKSFNRGE
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 7.2 +/- 3.2 days (adults) [2]
Metabolism
The drug is metabolized via opsonization via the reticuloendothelial system []
Vd
The volume of distribution (Vd) of drug is 7.8 +/- 5.1 L in pediatric and 4.8 +/- 2.1 L in adult []
Cross-matching ID
UNII
9927MT646M
DrugBank ID
DB00074
TTD ID
D06SBB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor alpha (IL2RA) TT10Y9E IL2RA_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Basiliximab
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Basiliximab and Azathioprine. Transplant rejection [NE84] [4]
Coadministration of a Drug Treating the Disease Different from Basiliximab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Basiliximab and Roflumilast. Asthma [CA23] [5]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Basiliximab and Teriflunomide. Hyper-lipoproteinaemia [5C80] [6]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Basiliximab and Denosumab. Low bone mass disorder [FB83] [7]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Basiliximab and Cladribine. Mature B-cell leukaemia [2A82] [5]
Alemtuzumab DMZL3IV Moderate Additive immunosuppressive effects by the combination of Basiliximab and Alemtuzumab. Mature B-cell leukaemia [2A82] [8]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Basiliximab and Tecfidera. Multiple sclerosis [8A40] [9]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Basiliximab and Siponimod. Multiple sclerosis [8A40] [4]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Basiliximab and Fingolimod. Multiple sclerosis [8A40] [10]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Basiliximab and Ocrelizumab. Multiple sclerosis [8A40] [11]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Basiliximab and Ozanimod. Multiple sclerosis [8A40] [5]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Basiliximab and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [12]
Efalizumab DMCKL5V Moderate Additive immunosuppressive effects by the combination of Basiliximab and Efalizumab. Psoriasis [EA90] [13]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Basiliximab and Canakinumab. Rheumatoid arthritis [FA20] [14]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Basiliximab and Rilonacept. Rheumatoid arthritis [FA20] [14]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Basiliximab and Golimumab. Rheumatoid arthritis [FA20] [15]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Basiliximab and Leflunomide. Rheumatoid arthritis [FA20] [6]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Basiliximab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [16]
⏷ Show the Full List of 17 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6879).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Cerner Multum, Inc. "Australian Product Information.".
5 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
6 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
7 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
8 Product Information. Campath (alemtuzumab) Berlex, Richmond, CA.
9 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
10 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
11 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
12 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
13 Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
14 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
15 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
16 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]